Sacituzumab tirumotecan

DELRAY BEACH, Fla., April 3, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Next Generation Drug Conjugates Market is projected to grow from about USD 15.75 billion in 2026 to USD 42.55 billion by 2035, at a CAGR of 11.7%. Browse 260 market data Tables and 60 Figures spread through 270 Pages and in-depth TOC on "Next Generation Drug Conjugates Market - Global Forecast to 2035" Next Generation Drug Conjugates Market Size & Forecast: Market Size Available for Years: 2026–2035 2026 Market Size: USD 15.75 billion 2035 Projected Market Size: USD 42.55 billion CAGR (2026–2035): 11.7% Next Generation Drug Conjugates Market Trends & Insights: By type, the peptide-radionuclide conjugate is projected to witness the highest CAGR of 14.6% between 2026 and 2035. By indication, breast cancer is expected to dominate the global next generation drug conjugates market in 2025 with a share of 45.9%. North America is projected to be the fastest-growing regional segment at a CAGR of 13.2% during the forecast period. Download PDF Brochure @ The growing prevalence of hematologic malignancies and solid tumors is a major driver for the next generation drug conjugates market. Additionally, continuous advancements in conjugation technologies, including improvements in targeting ligands, linker chemistry, payload design, and manufacturing processes, are enhancing the efficacy, safety, and scalability of these therapies. By product, The Enhertu segment accounted for the largest share of the global next generation drug conjugates market in 2025. the next generation drug conjugates market is segmented into Enhertu, Amvuttra, Pluvicto, Trodelvy, Sacituzumab Tirumotecan (SAC-TMT), Zilebesiran, 225Ac-PSMA-617, other commercialized products, and other pipeline products. The Enhertu dominated the market share in 2025, driven by its superior clinical efficacy, strong global adoption, and expanding approvals across multiple HER2-targeted indications, particularly in breast cancer. Its growing use in HER2-low populations and ongoing clinical trials in lung and gastric cancers further support its market leadership. Additionally, the increasing prevalence of breast cancer and the rising demand for targeted therapies continue to boost the uptake of Enhertu, reinforcing its dominant position in the global NGDC market. Request Sample Pages@ By Targeting ligand, Amino sugar is estimated to be the fastest-growing target ligand segment. The global next generation drug conjugates market is segmented by target ligand into antibodies, amino sugars, peptides, and other targeting ligands. In 2025, the amino sugar segment is projected to be the fastest growing during the forecast period, driven by its emerging role in targeted delivery and improved cellular uptake. Amino sugar-based ligands offer enhanced biocompatibility and potential for selective binding, supporting their increasing adoption in novel drug conjugate development and expanding research applications in precision oncology. North America accounted for the largest regional share in the global next generation drug conjugates market in 2025. North America accounted for the largest share of regional revenues in the next generation drug conjugates (NGDC) market and remains the primary growth engine. The region's dominance is driven by a high concentration of leading biopharmaceutical companies, advanced research institutions, and specialized cancer centers, along with strong regulatory support from the FDA and rapid adoption of innovative targeted therapies such as antibody-drug conjugates. Robust oncology pipelines, significant NIH and private funding, and an active clinical trials landscape position the US as the key innovation hub for NGDCs, while Canada contributes steadily through expanding healthcare infrastructure, increasing cancer research initiatives, and growing adoption of advanced oncology treatments. Inquire Before Buying@ Top Companies in Next Generation Drug Conjugates Market: The Top Companies in Next Generation Drug Conjugates Market include Alnylam Pharmaceuticals, Inc (US), Gilead Sciences, Inc (Immunomedics) (US), Novartis AG (Switzerland), AstraZeneca (UK), Daiichi Sankyo, Company Limited (Japan), Ionis Pharmaceuticals, Inc. (US), Rakuten Group, Inc. (US), Novo Nordisk (Dicerna Pharmaceuticals) (Denmark), ADC Therapeutics SA (Switzerland), Sanofi (France), Arrowhead Pharmaceuticals (US), and AbbVie, Inc (US). Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting Related Reports: Antibody Discovery Market - Global Forecast to 2030 Antibody Therapeutics Market - Global Forecast to 2028 Oligonucleotide Synthesis Market - Global Forecast to 2030 Peptide Synthesis Market - Global Forecast to 2029 Drug Discovery Services Market - Global Forecast to 2030 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency. To find out more, visit ™.com or follow us on Twitter , LinkedIn and Facebook . Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: [email protected] Visit Our Website: Logo - SOURCE MarketsandMarkets 21% more press release views with Request a Demo

BXLS funds innovation within the life sciences sector. Credit: Vector mall / Shutterstock.com. Private investment platform Blackstone closed a funding raise that has brought in $6.3bn in capital to support its ongoing life sciences investment strategy – marking the largest life sciences private fund ever raised. The firm’s dedicated BXLS platform will absorb this oversubscribed funding round, providing companies with capital to develop and commercialise new drugs and medical technologies across the entire lifecycle. In the last 12 months, BXLS has handed over nearly $2bn to various companies within the life sciences sector to fund their development and commercialisation journeys. This includes MSD (Merck & Co), which recently bagged $700m to support the development of its antibody-drug conjugate (ADC), sacituzumab tirumotecan , across various solid tumour indications. BXLS also poured $400m into Teva Pharmaceutical’s duvakitug development programme back in early March 2026, which is currently in late-stage trials for inflammatory bowel diseases like Crohn’s and ulcerative colitis. In February 2026, the investment platform teamed up with Johnson & Johnson (J&J) to co-fund future clinical trials of its acute myeloid leukaemia (AML) drug, bleximenib. Blackstone Life Sciences has previously secured 34 approvals for innovative medicines and devices it has backed, including blockbuster therapies like Alnylam Pharmaceuticals’ transthyretin amyloidosis (ATTR) therapy, Amvuttra (vutrisiran) and AbbVie & J&J’s Bruton’s tyrosine kinase (BTK) inhibitor, Imbruvica (ibrutinib). Taking a look at the life sciences investment landscape According to Blackstone Life Sciences’ global head, Nicholas Galakatos, this round highlights the firm’s “enduring conviction in the life sciences”, which remains one of its core areas of focus. This will be welcome news for the sector, which has been contending with a challenging funding landscape triggered by burgeoning interest rates and economic uncertainty in recent years. Geopolitical factors like tariffs are also currently shaping pharmaceutical investment and launch strategies . Despite these hurdles, there have been some positive signals hinting to the recovery of pharma funding. As per a report from GlobalData , parent company of Pharmaceutical Technology , the total value of venture capital investments made in the sector in Q4 2025 climbed 70.6% compared with Q3. This upward trend was also observed in the volume of investments, which saw a 30.4% uptick to 206 deals. GlobalData has also highlighted the shift in investor activity – especially in the cell and gene therapy (CGT) space – which has seen an enhanced interest in candidates in the Series B-stage , as investors become more selective and strategy-driven. In a previous conversation with Pharmaceutical Technology , LanceBio Ventures partner, Ilya Yasny, noted that early planning, adaptability, trust building and strong data make up the backbone of any successful startup, and that companies should always look to fulfil an unmet patient need.